Video
QUILT 3032 study shows efficacy of N-803 in BCG-unresponsive bladder cancer
Author(s):
“To have at the 2-year mark basically half the patients still without evidence of disease is really a step forward,” says Sam S. Chang, MD, MBA.
Video Player is loading.
Sam S. Chang, MD, MBA, discusses results from the phase 2/3 QUILT-3.032 trial showing the efficacy of the combination of BCG and the novel interleukin-15 superagonist N-803 in patients with BCG-unresponsive bladder cancer.
Chang is a professor in the Department of Urology, Patricia and Rodes Hart Professor of Urologic Surgery, and chief surgical officer and chief of the Division of Urologic Oncology at Vanderbilt Ingram Cancer Center.
Related Videos
Non–Muscle Invasive-Bladder Cancer Overview
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Related Content
April 28th 2025
